Alport syndrome overview

Revision as of 00:02, 10 July 2017 by Ahmed Younes (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Alport syndrome Microchapters


Patient Information


Historical Perspective



Differentiating Alport syndrome from other Diseases

Epidemiology and Demographics

Natural History, Complications and Prognosis


Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Echocardiography or Ultrasound

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alport syndrome overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Alport syndrome overview

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alport syndrome overview

CDC on Alport syndrome overview

Alport syndrome overview in the news

Blogs on Alport syndrome overview

Directions to Hospitals Treating Alport syndrome

Risk calculators and risk factors for Alport syndrome overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Alport’s syndrome (hereditary nephritis) is a familial nephropathy characterized by renal impairment, auditory manifestations, and may also have ocular defects. It has an X-linked form characterized by the mutation of COL4A5 gene on the long arm of X-chromosome, and another much less common autosomal recessive form characterized by the homogeneous mutation of COL4A3 or COL4A4 on chromosome 2. The mutation leads to abnormal alpha chain of type IV collagen, which is normally responsible for the structure and function of basement membranes in the body. Alport’s syndrome most commonly presents in childhood with persistent hematuria; a presentation that should always consider a range of more common differential diagnoses before the diagnosis of Alport’s syndrome is made. Prognosis of Alport’s syndrome is generally poor with inevitable progression to end-stage renal disease (ESRD) at varying rates. Management is by multidisciplinary approach, involving established and promising pharmacologic therapy along with renal replacement methods.


Template:WH Template:WS